论文部分内容阅读
目的:观察埃克替尼治疗晚期肺腺癌的疗效及安全性方法:收集2011年7月至2012年3月我院晚期肺腺癌患者共67例,均给予口服埃克替尼125mg,tid,直至疾病进展或出现无法耐受的不良反心。结果:67例中一线治疗者16例,二线及二线以上治疗者51例,总的客观缓解率为35.8%(24/67),疾病控制率为74.6%(50/67);行EGFR(Epidermal growth factor receptor,表皮生长因子受体)基因检测的18例患者中有15例EGFR基因突变阳性,客观缓解率为60%(9/15),疾病控制率为93.3%(14/15)疗效因素分析显示仅化疗方案数与客观有效率和疾病控制率有关系(P=0.034,P=0.044)。最常见的有不良反应皮疹、腹泻、皮肤瘙痒,发生率分别为20.9%、11.9%、9.0%,程度均较轻(Ⅰ度～Ⅱ度)。结论:埃克替尼治疗晚期肺腺癌,患者能获得较好的疗效及临床获益,且安全性好。
Objective: To observe the efficacy and safety of icotinib in the treatment of advanced lung adenocarcinoma.METHODS: A total of 67 patients with advanced lung adenocarcinoma in our hospital from July 2011 to March 2012 were enrolled. All patients were given ixitinib 125mg, tid Until disease progression or intolerable adverse reactions. Results: Sixty-six cases were treated with first-line therapy and 51 cases with second- and second-line therapy. The total objective response rate was 35.8% (24/67) and the disease control rate was 74.6% (50/67). Epidermal EGFR gene mutations were found in 15 of the 18 patients tested with EGFR gene mutation (60%, 9/15) and disease control rate (93.3%, 14/15) Analysis showed that only the number of chemotherapy regimens and objective efficiency and disease control rate (P = 0.034, P = 0.044). The most common adverse reactions rash, diarrhea, itchy skin, the incidence rates were 20.9%, 11.9%, 9.0%, were mild (Ⅰ degree ~ Ⅱ degree). Conclusion: Icotinib treatment of advanced lung adenocarcinoma, patients can get better efficacy and clinical benefit, and good safety.